The main objective of this study was to develop a polymeric drug delivery system for paclitaxel, intended to be intravenously administered, capable of improving the therapeutic index of the drug and devoid of the adverse effects of  Cremophor EL. To achieve this goal paclitaxel (Ptx)-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Ptx-PLGA-Nps) were prepared by the interfacial deposition method. The influence of different experimental parameters on the incorporation efficiency of paclitaxel in the nanoparticles was evaluated. Our results demonstrate that the incorporation efficiency of paclitaxel in nanoparticles was mostly affected by the method of preparation of the organic phase and also by the organic phase / aqueous phase ratio. Our data indicate that the methodology of preparation allowed the formation of spherical nanometric (,200 nm), homogeneous and negatively charged particles which are suitable for intravenous administration. The release behaviour of paclitaxel from the developed Nps exhibited a biphasic pattern characterised by an initial fast release during the first 24 h, followed by a slower and continuous release. The in vitro anti-tumoral activity of Ptx-PLGA-Nps developed in this work was assessed using a human small cell lung cancer cell line (NCI-H69 SCLC) and   compared to the in vitro anti-tumoral activity of the commercial formulation Taxol . The influence of Cremophor EL on  cell viability was also investigated. Exposure of NCI-H69 cells to 25 mg / ml Taxol resulted in a steep decrease in cell viability. Our results demonstrate that incorporation of Ptx in nanoparticles strongly enhances the cytotoxic effect of the drug  as compared to Taxol , this effect being more relevant for prolonged incubation times. 
travascular (i.v) administration [5] . Presently, the patibility and biodegradation of the polyesters makes  only available formulation for clinical use (Taxol ) them suitable candidates for pharmaceutical purposes consists of a solution of paclitaxel (6 mg / ml) in a [33] . Recently, some work on the use of PLGA  vehicle composed of Cremophor EL and dehynanoparticles as carriers for paclitaxel has been drated alcohol at a 50:50 (v / v) ratio. This vehicle has published [19, 20, 23] . Nevertheless, to our knowledge been associated with severe hypersensitivity rethere are no reports on the literature regarding the actions and has shown incompatibility with common incorporation of paclitaxel into PLGA nanoparticles PVC intravenous administration sets [6] [7] [8] [9] [10] . In order using the nanoprecipitation method. Besides being  to eliminate the Cremophor based vehicle and in an the simplest method for Nps preparation, involving attempt to increase the therapeutic efficacy of the only one step for dispersion of the non-toxic organic drug, alternative dosage forms have been suggested, phase in the aqueous phase, thus avoiding any including parenteral emulsions [11, 12] , liposomes purification procedure, it provides high yields of [13] [14] [15] , nanoparticles [16] [17] [18] [19] [20] and microspheres encapsulation of hydrophobic compounds, and the [21] [22] [23] [24] .
formation of particles exhibiting adequate features Among the new drug delivery systems, polymeric for i.v. administration. The resulting formulations nanoparticles have been considered as promising were extensively characterized regarding their size, carriers for anticancer agents. In fact, it has been morphology and charge. In vitro drug release studies demonstrated that a significant improvement in drug were also performed using the most promising specificity of action can be reached upon its incorpoformulation developed in this work. Finally, in vitro ration into nanoparticles, this effect being mainly anti-tumoral activity of paclitaxel incorporated in the attributed to changes in tissue distribution and pharnanoparticles was evaluated using a human small cell macokinetics [25, 26] . These modifications may conlung cancer cell line (NCI-H69). sequently result in a reduction in the side-effects and toxicity of the drug and in an increase in its therapeutic efficacy. Furthermore, it has been demon-2 . Materials and methods strated that nanoparticles can escape from the vasculature through the leaky endothelial tissue that 2 .1. Materials surrounds the tumor and thus accumulate in certain solid tumors [27, 28] . More recently, it was also Paclitaxel was a gift from Bristol Myers Squibb reported that nanoparticles can overcome the multi-(Portugal). PLGA copolymers (50 / 50; Resomer RG drug resistance phenotype mediated by glycoprotein-502H, MW 6000 and RG 502, MW 14 500) and the P leading to an increase in drug content inside the 75 / 25 PLGA copolymer (Resomer RG 755, MW neoplastic cells [29] . This finding is of great impor-63 600) were purchased from Boheringer Ingelheim.
 tance for the particular case of paclitaxel since Acetone pro analisi was supplied by Merck. Polox- acquired resistance to the drug has already been amer 188 (Symperonic F68) was obtained from ICI reported [30] . Other important advantages associated (ICH, France). Dichloromethane (DCM), acetonitrile with the use of nanoparticles include the ease of their and phosphoric acid (HPLC grade) were purchased preparation with well-defined biodegradable polyfrom Merck. The tetrazolium dye 3-(4,5-dimers (ex: PLGA) and their high stability in biomethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  logical fluids and during storage [31] .
(MTT) was obtained from Sigma. Cremophor EL Hence, the main goal of this work was to develop was kindly provided by BASF (BASF, Portugal). a polymeric drug delivery system for paclitaxel Water was purified by reverse osmosis (Milli-Q,
aiming at avoiding the use of Cremophor EL and Milipore ). improving the anti-tumoral efficacy of the drug.
For this purpose nanoparticles of PLGA contain-2 .2. Preparation of paclitaxel-loaded nanoparticles ing paclitaxel were prepared by the interfacial deposition (nanoprecipitation) method [32] . PLGA was Nanoparticles were prepared by the interfacial used in this study since the demonstration of biocomdeposition method as previously described by Fessi et al. [32] . Briefly, an organic solution of PLGA (100 directly to the polymer (also added as a powder) and mg) and paclitaxel (0.4 or 1 mg) in acetone (10 ml) this mixture was then solubilized in 10 ml of acetone was added to an aqueous poloxamer 188 solution (10 (method A); (ii) a solution of paclitaxel in acetone or 20 ml, 0.25%, w / v) under magnetic stirring at was prepared (final concentration of 0.4 or 1 mg / ml) room temperature. Following 15 min of magnetic and 1 ml of this solution added to the polymer, being stirring the acetone was removed under reduced the resulting mixture vortexed vigorously until compressure. To remove the non-incorporated drug, the plete dissolution of the polymer. The volume was obtained nanosuspension was filtered (S&S 'Filter completed to 10 ml with acetone immediately before paper circles', pore size 1 mm) and ultracentrifuged the addition of the organic phase to the aqueous twice at 61 7003g for 1 h at 4 8C (Beckman L-80 phase (method B). In addition, the effect of using ultracentrifuge equipped with a Ti-70 rotor). The copolymers of PLGA with different molecular supernatant containing the free drug was discarded weights and different organic / aqueous phase ratios and the pellet was freeze-dried for 24 h (Labconco were also investigated. Freeze Dry System-Freezone 6 Liter, Kansas City, MO, USA).
2 .3. Determination of paclitaxel content in the Drug-free nanoparticles were prepared according nanoparticles to the same procedure.
In an attempt to investigate the influence of The paclitaxel content in the PLGA nanoparticles various formulation parameters on drug incorporawas assayed by HPLC. For this purpose, optimition efficiency, different experimental conditions zation and validation of a method proposed by Wang were evaluated (Fig. 1) . Two distinct methods for et al. [21] were performed (data not shown). Briefly, the preparation of the organic phase were tested: (i) a a specific amount of lyophilized nanoparticles was specific amount of paclitaxel powder was added dissolved in 1 ml DCM and mixed with 5 ml of an acetonitrile:2 mM phosphoric acid solution (50:50, v / v incubated at 37 8C and shaken horizontally at 160 initial amount of drug ) 3 100 (1) strokes / min. At preselected time intervals, two flasks (mg) were withdrawn and nanospheres were separated by 2 .4. Physicochemical characterization ultracentrifugation. After removing the supernatant, the pellet was washed twice with distilled water and 2 .4.1. Particle size distribution and morphology lyophilized. The amount of residual paclitaxel in the Particle size distribution (mean diameter and polynanoparticles was determined by HPLC using the dispersity index) was determined by photon correlasame procedure as described above (Section 2.3). tion spectroscopy (PCS) using a Malvern Autosizer 2c (Malvern Instruments, UK). The analysis was 2 .6. Cells performed at a scattering angle of 908 at a temperature of 25 8C using samples appropriately diluted NCI-H69 cells, a human small cell lung cancer with ultra-purified water. For each sample, the mean (SCLC) cell line, were obtained from America Type diameter of three determinations was calculated.
Culture Collection (ATCC, Manassas, VA, USA). Values reported are the mean6standard deviation of Cells were cultured in suspension in RPMI-1640 at least three different batches of nanoparticles.
medium supplemented with 10% heat-inactivated The morphology of the nanospheres was ascerfetal bovine serum (FBS) (Biochrom, Berlin) and tained by Transmission Electronic Microscopy antibiotics (100 mg / ml of streptomycin and 100 (TEM) (CM-12, Philips, The Netherlands). A drop unit / ml of penicillin, Sigma) at 37 8C in a balanced of the nanoparticles suspension (10 ml) was placed air humidified incubator with an atmosphere of 5% on copper electron microscopy grids (Formvar CO . Cells were maintained in an exponential 2 filmed) and stained with a 2% (w / v) phosphotungstic growth phase by periodic dilutions with fresh acid solution (Sigma). After 30 s the sample was medium. washed with ultra-purified water and the excess fluid removed with a piece of filter paper. The dried 2 .7. In vitro anti-tumoral activity sample was then examined. 4 Briefly, 8310 viable cells / well were seeded in 2 .4.2. Surface charge 100 ml of growth medium in 96-well microtitre Nanoparticles were also characterized with respect plates (Costar, Cambridge, MA) [34] . Cells were to electrophoretic mobility and zeta (z ) potential then incubated with different concentrations of  using a Coulter DELSA 440 (Coulter Corporation, Taxol or paclitaxel-loaded nanoparticles, after Miami, FL). Samples from the prepared suspensions appropriate dilution of these formulations in 100 ml were diluted in ultra-purified water and placed in the of culture medium, for 24, 72, 120 or 168 h. In order measurement cell, with its position adjusted to cover to determine the cytotoxic effect of the vehicle  the previously determined stationary layer. The Cremophor EL and of the polymer used to prepare electric field applied was 10 V.
the nanoparticles, cells were also incubated with different dilutions of these reagents for the same 2 .5. In vitro release studies periods of time.
The effect of the different treatments on cell The in vitro release profile of paclitaxel from viability was assessed by the tetrazolium dye assay PLGA-Nps prepared with the Resomer RG 502 of Mosmann [35] . This assay depends on the cellular copolymer and containing 1% (w / w) of the drug was reductive capacity to metabolise the yellow tetraassessed by determining the residual amount of zolium salt, 3-[4,5-dimethylthiazol-2-yl]-3,5-paclitaxel present in the nanospheres. For that purdiphenyltetrazolium bromide dye (MTT), to a highly coloured formazan product. Briefly, at the end of the incubation period with the different formulations, cells were washed twice with phosphate-buffered saline solution (PBS, pH adjusted to 7.4) by centrifugation (10 min, 12003g). Cells were then incubated with 100 ml of a MTT solution (0.5 mg / ml) in RPMI culture medium without FCS and phenol red for 4 h at 37 8C. One hundred microlitres of an isopropanol acidic solution (isopropanol-HCl 0.04 N) were then added in order to dissolve the formazan crystals formed. method A only about 15% of the initial drug loading is incorporated in the nanoparticles, in contrast to the 100% of incorporation obtained when the organic phase was prepared by the method B. Therefore, this can be observed, for the two initial drug loadings latter method was selected to prepare all the other used (0.4 and 1%) the incorporation efficiency of Ptx formulations.
was very high ($90%) and independent of the Fig. 2B illustrates the influence of the copolymer molecular weight and composition of the copolymers molecular weight and composition on the I.E. of tested. paclitaxel. Nps were prepared from PLGA with Finally, the dependence of the I.E. of the drug on different molecular weight (MW) and with different the organic to aqueous phase ratio was also studied. lactic acid / glycolic acid (LA / GA) molar ratio. As Data presented in Fig. 2C clearly show that doubling the volume of the external aqueous phase, while cles as well as their homogeneous particle size maintaining constant the volume for the organic distribution. phase, resulted in a reduction of the incorporation
The presence of paclitaxel did not affect the size efficiency of the drug for all the copolymers tested.
of nanoparticles when considering the same copolyThis reduction was approximately 15% for Resomer mer. However, the characteristics of the copolymer RG 502H and approximately 20% for Resomer RG used were found to slightly affect the size of both 502 and Resomer RG 755 as compared to the drug-free PLGA-Nps and Ptx-PLGA-Nps, this effect formulation obtained with 1 / 1 organic / aqueous being dependent on the copolymer MW. phase ratio.
All formulations exhibited a net negative charge with z potential values ranging from 233.4 to 223.1 mV. Drug-free Nps prepared with the co-3 .2. Physicochemical characterization polymers RG 502H and RG 502 showed similar values for the z potential, while a significant reducAiming at predicting the in vivo behaviour of the tion in this parameter was observed when the developed Nps, the physicochemical properties of copolymer RG 755 was used. Regarding the formuPtx-Nps, in terms of their mean diameter, polydislations prepared in the presence of paclitaxel, drug persity index, morphology, electrophoretic mobility incorporation did not affect the z potential of the and z potential, were evaluated. The effect drug nanoparticles prepared with the copolymers RG incorporation on such properties was also studied by 502H and RG 755. However, a slight increase was comparing the results obtained with those for drugobserved for nanoparticles prepared with the polymer free PLGA-Nps (Table1). The MW and the com-RG 502. position of the copolymers used to prepare nanoparticles are also presented in order to facilitate the 3 .3. In vitro release studies interpretation of the obtained results. With respect to particle size analysis and as illustrated in Table 1, all The in vitro release behaviour of paclitaxel from systems prepared were nanometric (mean diameter PLGA-Nps prepared with the polymer RG 502 with ,200 nm) and exhibited a narrow size distribution an initial drug loading of 1% (w / w) is shown in Fig.  (polydispersity index ,0.1) . The same conclusion 4. As can be observed, the release behaviour of can be withdrawn from the TEM analysis. Reprepaclitaxel from the polymer matrix exhibited a sentative TEM microphotographs obtained with the biphasic pattern characterised by a fast initial release PLGA-Nps (Resomer RG 502) are presented in Fig. during the first 24 h, followed by a slower and 3A,B showing the spherical shape of the nanoparticontinuous release. After appropriate dilution of the different formulations obtained, mean diameter (MD) and polydispersity index (PI) were measured by PCS and electrophoretic mobility (EM) and z potential were determined by DELSA as described in Section 2.
.4. In vitro anti-tumoral activity
The cytotoxic activity of paclitaxel, both formu-  lated in Cremophor EL (Taxol ) (Fig. 5A ) and loaded in PLGA nanoparticles (Fig. 6) , was evaluated by assessing cell viability by the MTT assay using the NCI-H69 cell line. Cells were incubated with concentrations of paclitaxel ranging from 0.025 to 25 mg / ml. This range of concentrations was selected because it corresponds to plasma levels of the drug achievable in humans [36] .
As can be seen in Fig. 5A , a marked reduction in cell viability was observed when NCI-H69 cells were  incubated with 25 mg / ml Taxol for 24 h at 37 8C. At this concentration, the cell growth was almost totally inhibited after 72 h of incubation, this effect 96-well plates and incubated with different concentrations of both were diluted in PBS, incubated at 37 8C and shaken horizontally.
formulations for 24, 72, 120 or 168 h at 37 8C as described in At preselected time intervals, the released drug was separated by Section 2. Following the incubation, cell viability was determined ultracentrifugation and the residual amount of paclitaxel present in by the MTT assay and expressed as a percentage of control wells the nanospheres determined by HPLC as described in Section 2.
(cells without treatment). Results shown in this figure represent Each point represents the mean6standard deviation obtained from the mean6standard deviation obtained for at least three indepentriplicates of two samples. dent experiments performed in triplicate.
biological activity [37] [38] [39] , the possible contribution of this excipient to the in vitro cytotoxicity observed  when NCI-H69 cells were exposed to Taxol was also investigated. As can be shown in Fig. 5B , a significant reduction in cell viability was also observed when cells were exposed to 2.2 mg / ml of this excipient (added at the same concentration of  Cremophor EL present in a solution of 25 mg / ml   Taxol ). Similar to what was observed with Taxol ( Fig. 5A) , this reduction was more pronounced following 72 h of incubation, cell growth being almost totally inhibited following 120 h of incuba- tion. Still regarding Cremophor EL, it should be noted that at the lowest concentrations (0.022 and 0.0022 mg / ml) no cytotoxic effect was observed for the longest incubation times. Fig. 6A ,B illustrates the results obtained when paclitaxel-loaded nanoparticles were incubated with the NCI-H69 cells for different times at 37 8C. With respect to the dependence of cytotoxicity on the type of the copolymer used, it should be mentioned that for the Ptx-PLGA-Nps prepared with the copolymer respectively, this effect was shown to be independent of the concentration used. Nevertheless, for the being maintained for the other incubation times longest incubation time (168 h) a marked cytotoxic tested. It is interesting to note that no toxicity was effect could be observed for both 2.5 and 25 mg / ml. observed when cells were incubated with 2.5 mg / ml Under these conditions, Ptx-PLGA-Nps were able to  Taxol for 24 h. However, for lower concentrations mediate similar levels of toxicity to those observed  (0.025 and 0.25 mg / ml Taxol ) a 20% reduction in for 25 mg / ml of the commercially available formula- cell viability could be seen. For longer incubation tion of paclitaxel (Taxol ). times no significant differences in cytotoxicity were Paclitaxel loaded-nanoparticles obtained with the observed among the different concentrations tested RG 755 copolymer, showed a different behaviour  (0.025, 0.25 and 2.5 mg / ml Taxol ). However, as (Fig. 6B) . In this case, the incubation time seems to expected, for each of these concentrations an enbe the most critical parameter for paclitaxel activity. hancement in cytotoxicity with increasing time of After 24 h of incubation, no cytotoxic effect could be incubation was observed. Nevertheless, it should be observed for any of the concentrations tested. Inmentioned that cell growth was never completely creasing times of incubation resulted in an enhanceinhibited (approximately 30% of viable cells were ment of Ptx-PLGA-Nps cytotoxicity. After 168 h of determined even after 168 h of exposure).
incubation with this formulation, a reduction of  Since it is well recognized that Cremophor EL approximately 63% in cell viability was detected for  (the solvent employed in the Taxol ) has some all concentrations tested.
In order to determine any possible cytotoxic effect may be that a different interaction between paclitaxel attributed to the copolymers used to prepare the and the polymer occurs when they are both solubilnanoparticles, cell viability was also evaluated upon ized, thus leading to a different incorporation of the incubation of the cells with different concentrations drug in the nanoparticles. In fact, paclitaxel has a of drug-free nanoparticles. According to our results complex structure and previous studies have prono cytotoxic effect was observed upon incubation of vided evidence that its conformation in solution, as these formulations with cells. The results presented well as its molecular interactions, may be dependent reflect only the effect of the highest copolymer on the type of solvent and on its concentration in the concentration used (2.5 mg / ml), since similar results organic phase [42, 43] . Balasubramanian et al.
[43], were obtained for the other concentrations tested reported differences in paclitaxel conformation and (data not shown). molecular interactions when its concentration varied 24 23 A comparison of the results obtained for both from 10 to 10 M, values that are in the same formulations (Fig. 6A,B) , shows that after 168 h of range as those employing methods A and B, respecincubation with either 2.5 or 25 mg / ml of incorpotively. Besides, the polymer concentration is also 10 rated drug, Ptx-PLGA-Nps prepared with the RG times higher using method B which may also favours 502 copolymer were able to mediate higher levels of its interaction with the drug. toxicity than Ptx-PLGA-Nps prepared with the RG The organic / aqueous phase ratio is among the 755.
most critical parameters for the spontaneous formation of colloidal particles by the nanoprecipitation method [44] . Although the effect of this parameter 4 . Discussion on the particle size distribution has been previously investigated, there is still a lack of fundamental Paclitaxel is one of the most promising drugs information on its influence on the incorporation currently available for cancer therapy. Nevertheless, efficiency of drugs in nanoparticles prepared by this taking into account the problems associated with the methodology. In this work, an increase in the volume clinical use of the only available paclitaxel formulaof the external aqueous phase (1 / 2 ratio) caused a  tion (Taxol ), it can be deduced that the developdecrease in the incorporation efficiency of paclitaxel ment of a suitable carrier system for this drug is in PLGA nanoparticles. Preliminary studies perconsidered to be of prime importance. The main goal formed in our laboratory also revealed that this ratio of this work was to develop a polymeric delivery led to a significant decrease in the nanoparticles size system for paclitaxel intended to be intravenously as compared to that obtained when the 1 / 1 ratio was administered, capable of increasing the therapeutic used (data not shown). Based on our findings and on index of the drug and devoid of adverse effects.
the results reported in the literature, it is reasonable The interfacial deposition method (nanoprecipitato consider that the increase in the specific surface tion) is recommended for the incorporation of hydroarea caused by the formation of smaller nanodroplets phobic drugs into polymeric nanoparticles [32, 40] .
during the emulsification stage of the process, may Nevertheless, as described by several authors and facilitate the diffusion of the drug to the external also as demonstrated in this work, the establishment phase along with the solvent, leading to lower of a protocol that allows Nps precipitation, while incorporation efficiencies [45, 46] . It is also possible avoiding extensive diffusion of the drug along with that the smaller the size of the Nps, the lower the the solvent aiming at obtaining high values of drug capacity of the polymer matrix to incorporate the encapsulation is a challenging issue [41] . Taking into drug. account that both of the organic solutions tested have
The physicochemical characteristics of colloidal the same composition and the same concentration of systems, namely size and surface charge, are recogpaclitaxel at the moment of their addition into the nized to affect their physical stability and to sigaqueous phase, one possible explanation for the nificantly influence their interaction with the biodiscrepancy of the encapsulation efficiency results logical milieu after in vivo administration, as well as obtained from the two methods explored in this work the release rate of an incorporated substance and their interaction with cells [47, 48] . The method used followed by a slower and continuous release of the in this work allowed the instantaneous and reproducdrug. Similar patterns have been previously observed ible formation of Nps exhibiting diameters below for the release of paclitaxel from other PLGA 200 nm and low polydispersity indexes, indicating an polymeric systems [20, 56] . The burst release of homogeneous size distribution. As mentioned above, paclitaxel may be due to the dissolution and diffuthese findings were confirmed by the TEM data, sion of the drug that was poorly entrapped in the which also showed that nanospheres were spherical polymer matrix, while the slower and continuous in shape. Nps were shown to exhibit a negative release may be attributed to the diffusion of the drug surface charge, which can be attributed to the type of localised in the PLGA core of the nanoparticles. It polymer used and more specifically to the presence should be noted that the amount of drug released of polymeric carboxylic groups on the nanoparticle from the Nps developed in this work is within the surface [49, 50] . Nevertheless, the results presented range of the values reported for other PLGA systems slightly differ from those reported by other authors containing paclitaxel [20, 56] . [51] [52] [53] , which can be attributed to different conIn this study a small cell lung cancer cell line was ditions of Nps preparation (concentration of the used to determine the anti-tumoral activity of papolymer, concentration and type of drug and conclitaxel, either incorporated in PLGA-nanoparticles  centration and type of surfactant) and to the comor in the commercial formulation Taxol . The results position of the analysis medium used.
obtained clearly demonstrated that both the incubaWith respect to drug-free nanoparticles, a slight tion time and concentration play a major role in the effect of the copolymer composition on the surface in vitro cytotoxicity of paclitaxel. Cell toxicity was charge was observed. Nanoparticles prepared with higher for longer periods of incubation with the drug. RG 502H and RG 502 copolymers (at a 50 / 50 This finding is consistent with previous reports on LA / GA ratio) showed similar values of z potential, the in vitro cytotoxicity of paclitaxel against other while nanoparticles obtained with the RG 755 cotumour cell lines and is in agreement with the polymer exhibited a lower z potential. It has been mechanism of action of paclitaxel [36, 37] . In fact, described that the surface charge of nanoparticles for longer incubation periods a larger number of cells prepared with copolymers may depend on the proenter the G2 and M cell cycle phases during which portion of the different monomers [54] . It is also paclitaxel is more active [57] . This result suggests accepted that the presence of poloxamer 188, the that a drug delivery protocol that could maintain a emulsifier used during the preparation of nanopartitherapeutic concentration of paclitaxel for an extendcles, can contribute to a reduction in their surface ed period would be desirable in order to maximize its charge [54, 55] . In fact, it is known that this emulclinical efficacy. sifier tends to bind to the nanoparticles surface Although a marked reduction in cell viability was through hydrophobic interactions involving its polyobserved when NCI-H69 cells were incubated with  oxypropylene chains, while the hydrophilic polyoxy-25 mg / ml Taxol , cell growth being almost totally ethylene chains protrude into the surrounding inhibited for longer periods of incubation (72 h), medium, thus masking the negative surface charges these results should be analysed together with those  present in the nanoparticles. In the light of these observed for the Cremophor EL. In fact, an intriguconsiderations, it is possible that a stronger intering similarity in the extent of cell toxicity was action is established between poloxamer 188 and the observed upon incubation of the cells with either   RG 755 copolymer-based Nps (which has a more Taxol (25 mg / ml) or the excipient Cremophor EL hydrophobic surface due to the higher proportion of (used at a concentration equivalent to that existing in  LA / GA), as compared to the other copolymer used, a Taxol dose of 25 mg / ml). This result suggests thus justifying the lower values of z potential that the reduction in cell viability obtained with this observed.
concentration is not only due to paclitaxel activity

The release behaviour of paclitaxel from the but also to the presence of the Cremophor EL. polymer matrix exhibited a biphasic pattern charCuriously, when cells were incubated with 2.5 mg /  acterised by a fast initial release during the first 24 h, ml Taxol for 24 h no cytotoxic effect was observed, while for the lowest concentrations (0.25 and 0.025  mg / ml Taxol ), a decrease in cell viability was observed, a fact that can also be related to the  presence of Cremophor EL in the medium. In fact, it has been reported that, above certain concentrations (but below toxic concentrations),
Cremophor EL is able to block cells at the G1 phase of the cell cycle preventing them to enter G2 / M phases and thus hampering the cytotoxic effect of paclitaxel [37] [38] [39] . For the higher concentrations tested, significant differences in the cytotoxic effect of paclitaxelloaded nanoparticles were observed depending on the copolymer used, the RG 502 causing a larger extent MW) that are known to influence the release rate of a drug from a polymeric system [58, 59] .
In this work, a correlation can be established cytotoxicity observed is only attributed to the amount between the cytotoxicity results and the in vitro of paclitaxel released (since empty Nps are nonrelease kinetics of the drug from the PLGA-Nps. In toxic). The fact that total inhibition of cell growth fact, following 24 h of incubation a significant was only observed for the highest concentration amount of paclitaxel was released and thus available tested suggests that a threshold concentration needs to mediate some cytotoxicity. This effect increases to be reached in order that paclitaxel can develop with incubation time most likely due to the drug 100% of cell death. mechanism of action which requires cell division to
The enhancement of paclitaxel activity mediated occur.
by its incorporation into Nps can be explained by the The advantages of incorporating paclitaxel in the fact that these systems can act as a reservoir for developed PLGA nanoparticles are illustrated in Fig. paclitaxel, protecting the drug from epimerization 7. Incubation of the cells with 2.5 mg / ml of free and hydrolysis [60, 61] and providing not only a  paclitaxel (Taxol formulation) contributed to only sustained release of paclitaxel but also contributing 70% reduction in cell viability, while the same to the maintenance of its activity. In addition, it is concentration of the drug provided as Ptx-PLGA-Nps reasonable to consider that cells become more prone allowed a cytotoxic effect of almost 100%. It is to paclitaxel activity when the drug is delivered in  important to mention that for this latter condition the the absence of Cremophor EL (which is the case for cytotoxic effect was similar to that observed when Nps) since as reported above, this compound can  cells were incubated with 25 mg / ml Taxol , meanantagonize paclitaxel activity [37] [38] [39] . The mechaing that the same cytotoxic effect can be observed nism of drug release from the nanoparticles is also of with a 10-fold reduction in paclitaxel concentration.
crucial importance for the extent of paclitaxel activiFor the higher concentrations (25 mg / ml), similar ty. In this regard, two distinct but not exclusive  levels of toxicity were observed for Taxol and pathways can justify the enhancement of cytotoxic Ptx-PLGA-Nps. Nevertheless, it should be emphaactivity of anti-tumoral drugs incorporated into Nps:
 sized that in the case of Taxol a significant effect is (i) Nps can adsorb onto the cell membrane, leading  attributed to the diluent Cremophor EL (absent in to an increase in drug concentration near the cell the Nps), whereas in the case of Ptx-PLGA-Nps the surface, thus generating a concentration gradient that The results obtained showed that the methodology diluted in infusion solutions and stored in various containers, selected in this work allowed the instantaneous and
. Conclusions

